Core Insights - Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised 15,000 stock options and sold the corresponding shares for approximately $736,000, as reported in an SEC Form 4 filing [1][2][4] Company Overview - Maze Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for renal and metabolic diseases, leveraging precision genetics [7] - The company has a market capitalization of $1.6 billion and reported a net income of -$126.13 million over the trailing twelve months [5] - The stock price as of Wednesday was $32.78, with a significant one-year price change of 180% [5] Pipeline and Clinical Progress - The company is advancing small molecule precision medicines targeting renal, cardiovascular, and metabolic diseases, with lead candidates including MZE829 (APOL1 inhibitor) and MZE782 (SLC6A19 inhibitor) [10] - Recent Phase 2 data for MZE829 demonstrated a 35.6% reduction in proteinuria, with half of the patients achieving at least a 30% reduction, indicating potential for delayed disease progression [12] - Certain subgroups, such as FSGS patients, showed even stronger responses, with a 61.8% reduction in proteinuria [12] Market Reaction - Despite reporting positive topline data from its Phase 2 HORIZON Trial of MZE829, shares of Maze Therapeutics fell by 33% on Wednesday, attributed to a pre-planned liquidity event related to Bernstein's stock option exercise [11][12] - The stock had been trading at elevated levels prior to the decline, reflecting optimism around the company's proof-of-concept in a genetically defined kidney disease population [12][13]